Reckitt Bids To Delay Mucinex Competition With Bioequivalance Petition
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm's citizen petition could substantially delay generic competition if private-labelers need the four years it took Mucinex originator Adams, which Reckitt acquired in 2008, to develop a modified-release guaifenesin product.